Tempus AI: Leveraging Acquisitions and Partnerships to Drive Growth

Tempus AI is a precision technology company with strong growth momentum due to strategic acquisitions and partnerships. The company recently partnered with AstraZeneca and Pathos, receiving $200 million, and is expected to benefit from the collaboration. I am bullish on Tempus AI, driven by the potential of precision technology to transform the healthcare industry.

Tempus AI (TEM) and NVIDIA (NVDA) are two prominent players in the AI-powered healthcare sector, each with its unique strengths and growth potential. Tempus AI, a precision technology company, has seen significant growth due to strategic acquisitions and partnerships, while NVIDIA continues to lead in AI infrastructure for healthcare.

Tempus AI: Strong Growth and Strategic Partnerships

Tempus AI reported a 75% year-over-year revenue growth in the first quarter of 2025, driven by strong momentum in its core genomics and data businesses [1]. The company's partnerships, such as the $200 million deal with AstraZeneca and Pathos, are expected to benefit Tempus AI, as it aims to build the world's largest oncology foundation model. Tempus AI is also well-positioned to expand its role in drug discovery, diagnostics, and clinical decision-making, with over 300 petabytes of clinical data and $1 billion in contract value [1].

NVIDIA: Leading AI Infrastructure in Healthcare

NVIDIA continues to transform the healthcare and pharmaceutical landscape through strategic partnerships, AI infrastructure, and new generation AI technologies [1]. Collaborations with industry giants like Novo Nordisk and research organizations such as DCAI have enabled advanced simulations and large-scale biomedical language model training. NVIDIA's platforms like Clara and BioNeMo are revolutionizing patient care, clinical trial management, and pharmaceutical development, showcasing real-world gains [1].

Comparing Valuation and Price Targets

Tempus AI is trading at a forward 12-month price-to-sales (P/S) ratio of 7.84, below its median of 8.11 over the last year, while NVIDIA's forward sales multiple sits at 18.96, above its last one-year median of 17.81 [1]. Analysts suggest that Tempus AI may offer a better short-term opportunity in the AI-health tech space, with an average price target representing a 5.3% increase from the last closing price, compared to NVIDIA's 5.1% increase [1].

Conclusion

Both Tempus AI and NVIDIA carry a Zacks Rank #3 (Hold), reflecting solid but balanced near-term outlooks within the AI in health tech niche [1]. Tempus AI stands out with stronger year-to-date gains, faster revenue growth, expanding AI partnerships, and a more attractive valuation. While NVIDIA plays a critical role in powering healthcare AI infrastructure, its higher valuation limits near-term upside. Given current price targets, Tempus AI may offer a better short-term opportunity in the AI-health tech space.

References

[1] https://finance.yahoo.com/news/tempus-ai-nvidia-smarter-bet-173000139.html